Clinical and hemodynamic efficacy ofprestarium and its role in the treatment of chronic pulmonary heart


如何引用文章

全文:

详细

Aim. To assess clinical efficiency and safety of ACE inhibitor prestarium (Servier, France) with specification of its effects on central and pulmonary hemodynamics, hepatic blood flow, indications in patients with chronic pulmonary heart (CPH).
Material and methods. 42 patients with chronic obstructive bronchitis (COB) complicated by CPH
entered the trial. The patients were divided into two groups. Group 1 (n = 26) received standard therapy plus prestarium (2-4 mg/day), group 2 (n = 16) received only standard combined therapy. The
examinees have undergone ultrasonic investigation of the heart and liver in Doppler modes, ECG
monitoring, examination for external respiration function, lipid peroxidation activity, antioxidant blood
defense.
Results. Group 1 demonstrated earlier positive response. It was found that improvement in functional
class of cardiac failure induced by prestarium and less frequent episodes of arrhythmia directly correlated. Positive changes were stated in central and hepatic hemodynamics, systolic pressure in the pulmonary artery lowered more significantly than in the control group.
Conclusion. If COB patients have symptoms of right ventricular failure, they are recommended to take
prestarium in a daily dose 0.004g for 4 weeks to improve intracardiac and hepatic hemodynamics, reduce systolic pressure in the pulmonary artery and number of prognostically unfavourable arrhythmic
episodes.

参考

  1. Авдеев С. Н., Соколов А. С, Чучалин А. Г. Применение отечественного симпатомиметика вентокола при тяжелом обострении хронической обструктивной болезни. Пульмонология 1999; 2: 24-30.
  2. Федосова Н. Н., Оферкин А. И., Крейнес В. М. и др. Взаимосвязь электрофизиологических параметров сердца с газовым составом крови и показателями гемодинамики у больных хроническим обструктивным бронхитом. Тер. арх. 2001; 3:37-40.
  3. Казанбиев Н. К. Декомпенсированное легочное сердце. Актуальные вопросы лечения. Клин. мед. 1996; 4: 11 - 14.
  4. Багирова Г. Г., Баталина М. В. Лечение хронической сердечной недостаточности у больных с митральными и аортальными пороками сердца ревматической этиологии. Тер. арх. 2000; 9: 63-66.
  5. Бойцов С. А. Хроническая недостаточность кровообращения. Современные аспекты лечения. Гедеон Рихтер в СНГ 2000; 1: 24-27.
  6. Мартынов А. И., Степура О. Б., Гаджиев А. Н. и др. Применение ингибиторов ангиотензин-превращающего фермента при артериальной гипертонии (по материалам XXI-XXII конгрессов европейского общества кардиологов). Клин. мед. 2001; 6: 71-73.
  7. Butorov [. V., Usatai A., Bodrug N. I., Shkolinik M. Tratamentue dereglarilor hemodinamicii in bronhopneumopatiile obstructive cronice. (Recomandari metodice). Chisinau, 1998.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Consilium Medicum, 2003

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


##common.cookie##